Freeline Therapeutics (NASDAQ:FRLN) Stock Price Down 0.8%

Freeline Therapeutics Holdings plc (NASDAQ:FRLNGet Rating) shares fell 0.8% on Tuesday . The stock traded as low as $0.65 and last traded at $0.68. 24,408 shares changed hands during trading, a decline of 93% from the average session volume of 348,682 shares. The stock had previously closed at $0.69.

Analyst Upgrades and Downgrades

FRLN has been the subject of a number of analyst reports. BTIG Research decreased their price target on Freeline Therapeutics from $10.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, August 11th. HC Wainwright reduced their price objective on shares of Freeline Therapeutics from $20.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, August 22nd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Freeline Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Freeline Therapeutics Stock Performance

The stock has a fifty day simple moving average of $0.73 and a two-hundred day simple moving average of $0.81. The stock has a market cap of $44.18 million, a price-to-earnings ratio of -0.24 and a beta of 0.20.

Institutional Investors Weigh In On Freeline Therapeutics

Several hedge funds have recently modified their holdings of FRLN. TFG Asset Management GP Ltd lifted its position in shares of Freeline Therapeutics by 6.4% in the 3rd quarter. TFG Asset Management GP Ltd now owns 4,000,000 shares of the company’s stock worth $2,800,000 after purchasing an additional 239,492 shares during the period. Syncona Portfolio Ltd increased its stake in Freeline Therapeutics by 645.7% in the first quarter. Syncona Portfolio Ltd now owns 21,997,620 shares of the company’s stock valued at $5,841,000 after purchasing an additional 19,047,620 shares in the last quarter. Eventide Asset Management LLC grew its stake in shares of Freeline Therapeutics by 3.5% in the 1st quarter. Eventide Asset Management LLC now owns 3,606,192 shares of the company’s stock valued at $3,970,000 after buying an additional 120,536 shares during the period. UBS Group AG bought a new stake in Freeline Therapeutics in the 1st quarter valued at about $565,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Freeline Therapeutics by 112.5% in the 1st quarter. Renaissance Technologies LLC now owns 446,412 shares of the company’s stock worth $500,000 after purchasing an additional 236,312 shares in the last quarter. Institutional investors and hedge funds own 58.48% of the company’s stock.

Freeline Therapeutics Company Profile

(Get Rating)

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.

Featured Articles

Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.